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a b s t r a c t
Benznidazole is the main drug used to treat Trypanosoma cruzi infections. However, frequent instances
of treatment failure have been reported. To better understand potential resistance mechanisms, we ana-
lysed three clones isolated from a single parasite population that had undergone benznidazole-selection.
These clones exhibited differing levels of benznidazole-resistance (varying between 9 and 26-fold), and
displayed cross-resistance to nifurtimox (2 to 4-fold). Each clone had acquired a stop-codon-generating
mutation in the gene which encodes the nitroreductase (TcNTR) that is responsible for activating nitro-
heterocyclic pro-drugs. In addition, one clone had lost a copy of the chromosome containing TcNTR.
However, these processes alone are insufﬁcient to account for the extent and diversity of benznidazole-
resistance. It is implicit from our results that additional mechanisms must also operate and that T. cruzi
has an intrinsic ability to develop drug-resistance by independent sequential steps, even within a single
population. This has important implications for drug development strategies.
© 2014 The Authors. Published by Elsevier B.V. All rights reserved.
Chagas disease, which is caused by infection with Trypanosoma
cruzi, is the most important parasitic infection in South America.
As a result of mobility and migration, the disease is also becoming
a global public health issue [1,2], with large numbers of infected
individuals now resident in the USA and Europe, for example. The
nitroheterocyclic agents benznidazole and nifurtimox are the only
drugs currently used to treat T. cruzi infections. However, they
have several drawbacks. Their efﬁcacy against chronic stagedisease
remains uncertain, their therapeutic schedules can stretch over
several months, and toxic side effects are a common problem [3].
In addition, parasite strains refractory to treatment are frequently
observed [4].
Benznidazole and nifurtimox are pro-drugs and both are acti-
vated within the parasite by a mitochondrial NADH-dependent
type-I nitroreductase (TcNTR), which utilises FMN as a co-factor
[5]. The reduction of benznidazole results in the generation of the
cytotoxic metabolite glyoxal [6], while nifurtimox reduction leads
to the production of an unsaturated open-chain nitrile which has
 This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution and
reproduction in any medium, provided the original author and source are credited.
∗ Corresponding author. Tel.: +44 20 7927 2330; fax: +44 20 7636 8739.
E-mail addresses: monica.caroline@lshtm.ac.uk (M.C.O. Campos),
lleon@ioc.ﬁocruz.br (L.L. Leon), martin.taylor@lshtm.ac.uk (M.C. Taylor),
john.kelly@lshtm.ac.uk (J.M. Kelly).
trypanocidal properties [7]. Cross-resistance to nitroheterocyclic
drugs can be readily selected in the laboratory [5,8,9], and can be
associated with the loss of one copy of the chromosome containing
the TcNTR gene [5,8]. Mutations within the FMN-binding region
of TcNTR, which result in loss of enzyme activity, have also been
identiﬁed in drug-resistant parasites [8]. However, other resistance
mechanisms, not involving TcNTR, might operate. For example,
instances where resistance to nifurtimox occurs independently of
benznidazole-resistance have been reported [10]. Likewise, wide
natural variations in benznidazole-sensitivity have been identiﬁed
in Colombian isolates (EC50 4–30M), which are not associated
with changes in the TcNTR sequence [8].
To gain new insights into mechanisms that give rise to resis-
tance against nitroheterocylic drugs, we examined three T. cruzi
clones (Y strain) derived from a single population which had been
selected for resistance by exposure to increasing concentrations
of benznidazole [11]. When these parasites were grown in culture
in the absence of benznidazole, the drug-resistant clones grew at
about half the rate of the parental non-resistant cells, which had
a doubling time of 33h (Fig. 1A). However, there were no signiﬁ-
cant differences in the rate of amastigote replication or the extent
of infectivity between the parental parasites and any of the drug-
resistant clones (Fig. 1B–D). Surprisingly, assessment of the level of
benznidazole-resistance revealed signiﬁcant differences between
clones, ranging from 9 to 26-fold (Fig. 1E and G). These results
suggest that different and/or additional mechanisms must be con-
tributing to benznidazole-resistance in each case.Wealso observed
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Fig. 1. Characterisation of benznidazole-resistant T. cruzi clones. (A) Growth curves of parental anddrug-resistant clones. Epimastigoteswere cultured as describedpreviously
[15] in 25 cm2 cell culture ﬂasks (in triplicate) at 28 ◦C and parasite proliferation monitored by counting using a Neubauer chamber. (B–D) Rat skeletal myoblast L6 cells were
cultured on glass cover slips in 24-well plates (3×105 cells perwell) for 24h in RPMI-1640/10% FBS at 37 ◦C in 5%CO2. These cellswere then infected overnightwithmetacyclic
trypomastigotes obtained from stationary phase epimastigote cultures (5:1 parasite/host cell). Non-internalised parasites were removed by at least three washes. After 5
days, cells were washed twice with PBS, ﬁxed with methanol and stained with Giemsa. Average values for the percentage (%) infected cells and the number of amastigotes
were established by examination of at least 200 L6 cells for each parasite clone. Experiments were performed in triplicate, and the values shown are the mean± standard
deviation of the three experiments. No statistical difference was observed among parental parasites and clones following one-way analysis of variance (ANOVA). (E–G) To
determine the level of drug-resistance, epimastigotes were seeded into 48-well microtitre plates at 2.5×106 parasitesml−1 at a range of benznidazole (BNZ) (Rochagan)
or nifurtimox (NFX) (Lampit® , Bayer) concentrations for 6 days at 28 ◦C. Cell counting was carried out to determine the EC50 values (half maximal effective concentration).
Experiments were performed in triplicate (with 3 independent counts in each case) and the values shown are the mean± standard deviation. The fold resistance of each clone
to benznidazole and nifurtimox are indicated above the bars. The benznidazole-resistance levels of the three clones were signiﬁcantly different from each other (P<0.0001).
In terms of nifurtimox-resistance, each of the clones was signiﬁcantly more resistant than the parental parasites (P<0.0001). The levels of resistance displayed by clones 2
and 3 were not statistically different from each other, but both were signiﬁcantly less than clone 1 (P<0.0001).
that each clone was cross-resistant to nifurtimox, at levels ranging
from 2 to 4-fold (Fig. 1F and G). It can be inferred that the mech-
anism responsible for cross-resistance is insufﬁcient of itself, to
account for the complete extent and variability of benznidazole-
resistance. In previous cases of cross-resistance, a clear linkage
between the levels observed for benznidazole and nifurtimox has
been reported [5,8].
As TcNTR is the main activator of both benznidazole and
nifurtimox, we examined the structure and expression of the
corresponding gene in each of the resistant clones. Southern
blotting revealed an absence of gross rearrangements in the struc-
ture of TcNTR. Similarly, karyotypic analysis failed to reveal any
major changes in chromosome organisation in the resistant clones,
although there was variation in the ploidy of the 1.1 and 1.6Mb
chromosome homologues that contain the TcNTR gene (Fig. 2A).
In the parental Y strain and drug-resistant clones 2 and 3, the
smaller homologue is present in at least 2 copies, whereas in clone
1, the ratio equates to 1:1. Genome plasticity has been commonly
observed in T. cruzi [12] and chromosome loss has been associ-
ated with benznidazole-resistance [5,8]. In Y strain, the existence
of triploidy in thecaseof somechromosomeshasalsobeenreported
[13].
Whenweexamined thesequenceof theTcNTRgenes in thedrug-
resistant clones, we found a C/T transition at position 568 in each
case (Fig. 2B andC). This generates a stop codon (TGA) in themiddle
of the gene, resulting in a truncated protein deﬁcient in the puta-
tive carboxyl terminal FMN-binding site. To determinewhether the
parasites were homozygous for this mutation, we used a diagnos-
tic PCR with primers designed to speciﬁcally amplify the parental
and mutated copies of the gene (Fig. 2D). The results showed that
clones 1 and 2 were homozygous, whereas clone 3 had retained a
copy of the non-mutated parental allele. These results were con-
ﬁrmed by sequencing multiple amplicon fragments derived from
3 independent PCRs in the case of each clone. Interestingly, when
we examined the level of TcNTR RNA expression by Northern blot-
ting, we observed an increased abundance in each of the resistant
clones (Fig. 2E). Onepossibility is that translation of an inactive pro-
tein results in a metabolic feedback loop that acts to stabilise the
TcTNR transcript, or to otherwise increase the level of transcript
expression. The biological role of TcNTR has yet to be unequivo-
cally demonstrated, but evidence suggests that it may function as
a NADH-ubiquinone oxidoreductase [6,14].
Ourdata indicate that several sequential eventshada role inpro-
ducing the range of resistance phenotypes. The most parsimonious
explanation is that the ﬁrst step involved the generation of a stop
codon in a TcNTR allele (Fig. 2B) resulting in a progenitor cell with
reduced capacity to activate nitroheterocycles. It can be inferred
that the remaining intact copies of TcNTR were then removed by
gene conversion (clones 1 and 2) and/or loss of one copy of the
1.1Mb chromosome homologue (clone 1). Furthermore, additional
mechanisms must also have acted independently in the cases of
clones 1 and 2, and contributed to the enhanced level of benznida-
zole (but not nifurtimox) resistance. Previous studies [5,8] have
shown that TcNTR null mutants display 6- to 10-fold benznidazole-
resistance, whereas with clone 2 and the TcNTR heterozygote clone
3, we observed 26 and 14-fold resistance, respectively. These addi-
tional mechanisms are unknown, but it is clear that they do not
result in cross-resistance to nifurtimox. In the absence of evidence
for active uptake in T. cruzi, such resistance mechanisms could
involve enzymes or pathways that operate to protect the para-
site from toxic products of benznidazole reduction [6], or from
enhanced efﬂux mechanisms [11].
In this paper, we show that at least three distinct mechanisms
act in concert to generate high levels of benznidazole-resistance
within a single population. This intrinsic capacity of T. cruzi to
rapidly acquire drug-resistance by different routesmay explain the
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Fig. 2. Analysis of the structure and expression of the TcNTR gene frombenznidazole-resistant parasites. (A) Chromosomal DNA from the parental T. cruziY strain (P) and three
drug resistant clones (1–3) was immobilised in agar blocks and fractionated by a Bio-Rad CHEF Mapper system using an auto-algorithm set to the designated molecular mass
range [12] (left hand image). Chromosomes from Saccharomyces cerevisiae (Bio-Rad, Hercules, CA, USA) were used as molecular mass standards. After Southern hybridisation
using a radiolabelled TcNTR probe, the membrane was autoradiographed (right hand image). (B) Schematic of the TcNTR gene showing the region corresponding to the N-
terminal extension and putative FMN-binding regions [8,16]. The position of the C/T transition that generates a stop codon and the locations of primers used to differentiate
betweenwild type andmutated genes are shown, togetherwith the sequence of the reverse primers. (C) Electropherograms identifying the C/T transition inwild type (upper)
and mutated (lower) genes (GenBank accession number KF731779). (D) Products generated following ampliﬁcation of the TcNTR gene fragment using the primers shown in
(B). PCRs were carried out using 30 ampliﬁcation cycles; 96 ◦C for 30 s, 70 ◦C (wild type reverse primer) or 65 ◦C (mutation-containing reverse primer) for 30 s, 72 ◦C for 90 s,
and a ﬁnal extension step at 72 ◦C for 10min. Upper inset, wild type reverse primer; lower inset, mutant reverse primer. (E) Northern blot analysis of RNA from T. cruzi Y
strain (P) and three drug resistant clones (1–3). Upper inset, autoradiograph following hybridisation with radiolabelled TcNTR probe; lower inset, ethidium bromide stained
gel as loading control.
widely reported treatment failures with this drug. Furthermore,
it may have serious implications for the prospects of developing
anti-parasitic drugs to treat Chagas disease.
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